Form 8-K - Current report:
SEC Accession No. 0001193125-25-083523
Filing Date
2025-04-17
Accepted
2025-04-17 08:06:48
Documents
16
Period of Report
2025-04-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d915073d8k.htm   iXBRL 8-K 39794
2 EX-10.1 d915073dex101.htm EX-10.1 84697
3 EX-99.1 d915073dex991.htm EX-99.1 13493
7 GRAPHIC g915073g0417062538440.jpg GRAPHIC 2585
  Complete submission text file 0001193125-25-083523.txt   299763

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA avir-20250416.xsd EX-101.SCH 2859
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20250416_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20250416_pre.xml EX-101.PRE 11267
18 EXTRACTED XBRL INSTANCE DOCUMENT d915073d8k_htm.xml XML 3640
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 25844351
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)